Prologis (PLD) Cut to “Hold” at ValuEngine

ValuEngine downgraded shares of Prologis (NYSE:PLD) from a buy rating to a hold rating in a research note released on Thursday.

Several other research analysts have also recently issued reports on PLD. JPMorgan Chase & Co. raised Prologis from a neutral rating to an overweight rating in a report on Tuesday, March 27th. Citigroup raised Prologis from a neutral rating to a buy rating and set a $72.00 price target on the stock in a report on Friday, April 6th. Jefferies Financial Group raised Prologis from a hold rating to a buy rating in a report on Thursday, April 12th. BMO Capital Markets reaffirmed a buy rating and issued a $68.00 price target on shares of Prologis in a report on Tuesday, April 17th. Finally, Robert W. Baird set a $73.00 price target on Prologis and gave the company a buy rating in a report on Tuesday, April 24th. Three analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Prologis currently has a consensus rating of Buy and a consensus target price of $70.13.

Get Prologis alerts:

NYSE PLD opened at $62.44 on Thursday. The firm has a market capitalization of $33.30 billion, a price-to-earnings ratio of 21.91, a P/E/G ratio of 4.32 and a beta of 0.80. Prologis has a 1 year low of $58.28 and a 1 year high of $67.53. The company has a current ratio of 0.39, a quick ratio of 0.66 and a debt-to-equity ratio of 0.50.

Prologis (NYSE:PLD) last posted its quarterly earnings results on Tuesday, July 17th. The real estate investment trust reported $0.71 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.71. The company had revenue of $621.00 million for the quarter, compared to analysts’ expectations of $557.43 million. Prologis had a return on equity of 10.10% and a net margin of 74.17%. The firm’s revenue was down 18.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.84 earnings per share. analysts anticipate that Prologis will post 3.02 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, June 29th. Shareholders of record on Thursday, June 14th were given a dividend of $0.48 per share. This represents a $1.92 annualized dividend and a yield of 3.07%. The ex-dividend date of this dividend was Wednesday, June 13th. Prologis’s payout ratio is 68.33%.

In other Prologis news, Director Jeffrey L. Skelton sold 3,618 shares of Prologis stock in a transaction that occurred on Monday, May 7th. The shares were sold at an average price of $65.41, for a total transaction of $236,653.38. Following the transaction, the director now directly owns 47,708 shares in the company, valued at approximately $3,120,580.28. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Michael S. Curless sold 14,568 shares of Prologis stock in a transaction that occurred on Thursday, June 7th. The stock was sold at an average price of $66.07, for a total transaction of $962,507.76. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,869 shares of company stock worth $3,187,687. Corporate insiders own 1.31% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Centersquare Investment Management LLC purchased a new position in shares of Prologis during the 1st quarter valued at $370,841,000. BlackRock Inc. grew its holdings in shares of Prologis by 2.4% during the 1st quarter. BlackRock Inc. now owns 54,695,555 shares of the real estate investment trust’s stock valued at $3,445,272,000 after acquiring an additional 1,307,023 shares in the last quarter. Nuveen Asset Management LLC grew its holdings in shares of Prologis by 53.0% during the 1st quarter. Nuveen Asset Management LLC now owns 2,329,409 shares of the real estate investment trust’s stock valued at $146,729,000 after acquiring an additional 807,035 shares in the last quarter. Resolution Capital Ltd grew its holdings in shares of Prologis by 22.8% during the 1st quarter. Resolution Capital Ltd now owns 3,485,623 shares of the real estate investment trust’s stock valued at $219,559,000 after acquiring an additional 647,314 shares in the last quarter. Finally, Millennium Management LLC grew its holdings in shares of Prologis by 7,788.6% during the 1st quarter. Millennium Management LLC now owns 566,640 shares of the real estate investment trust’s stock valued at $35,693,000 after acquiring an additional 559,457 shares in the last quarter. Hedge funds and other institutional investors own 94.19% of the company’s stock.

About Prologis

Prologis, Inc is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of March 31, 2018, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 683 million square feet (63 million square meters) in 19 countries.

Featured Article: Book Value Per Share in Stock Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Buy DCB Bank; target of Rs 223: Cholamandalam Securities

Cholamandalam Securities' research report on DCB Bank

DCB��s advances continued to grow at a healthy pace (30.6% YoY, 4.5% QoQ) to INR 212bn in 1QFY19. Commercial Vehicles & Corporate segments witnessed higher growth (56.7% and 48% YoY respectively), although their relative share in overall portfolio continued to remain unchanged at 6% and 17% respectively.SME and Agricultural credit grew at 42.5% and 38.3% YoY respectively. The bank targets to double its overall asset portfolio in the next 3 years.

Outlook

DCB trades at 1.5X FY20E P/ABV and 11.7X FY20E P/E.� Healthy loan book growth, branch expansion and well-maintained asset quality paints a positive picture for the bank. This apart, considering its efforts to contain the cost to income ratios, to maintain healthy return ratios despite expected pressure on NIMs, we give the stock a BUY rating with a target price of INR 223, assigning a FY20E P/ABV of 2X.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Read More First Published on Jul 20, 2018 05:12 pm

Where Did Major Pharma Short Sellers Go?

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.

The White House has promised reforms in the health care sector, such as changing the bidding process for drugs and shortening the FDA approval process. It is yet to be seen how much headway they can actually make with these reforms.

Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.

The June 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.

Short interest in Pfizer Inc. (NYSE: PFE) decreased to 59.17 million shares from the previous 64.69 million. The stock was last seen trading at $37.21, within a 52-week range of $32.32 to $39.43.

The number of Merck & Co. Inc. (NYSE: MRK) shares short decreased to 17.15 million from 21.87 million in the previous period. Its shares were trading at $61.90, in a 52-week range of $52.83 to $66.41.

Teva Pharmaceutical Industries Ltd.��s (NYSE: TEVA) short interest decreased to 44.39 million from the previous level of 47.70 million. Shares were trading at $23.75, in a 52-week range of $10.85 to $33.82.

Bristol-Myers Squibb Co. (NYSE: BMY) short interest increased to 14.69 million shares from the previous reading of 14.50 million. Shares were last seen at $55.75, in a 52-week range of $49.96 to $70.05.

The number of shares short in AbbVie Inc. (NYSE: ABBV) decreased to 33.27 million from the previous 38.44 million. The stock was trading at $94.96, and its 52-week range is $69.38 to $125.86.

Eli Lilly and Co.��s (NYSE: LLY) short interest decreased to 11.49 million shares from the previous 12.81 million. The stock was trading at $87.56. The 52-week range is $73.69 to $89.09.

ALSO READ: The 5 Most Shorted NYSE Stocks

Zacks Investment Research Upgrades Greenhill & Co., Inc. (GHL) to “Buy”

Greenhill & Co., Inc. (NYSE:GHL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday. The firm currently has a $32.00 price target on the financial services provider’s stock. Zacks Investment Research‘s price objective indicates a potential upside of 7.38% from the company’s previous close.

According to Zacks, “GREENHILL & CO., Inc. is a leading independent investment bank that provides financial advice on significant mergers, acquisitions and restructurings; assists private funds in raising capital from investors; and manages merchant banking funds. It acts for clients located throughout the world from its offices in New York, London, Frankfurt, Toronto, Dallas and San Francisco. “

Get Greenhill & Co. Inc. alerts:

GHL has been the subject of several other reports. ValuEngine upgraded shares of Greenhill & Co., Inc. from a “hold” rating to a “buy” rating in a report on Thursday, May 17th. Sandler O’Neill reiterated a “hold” rating and issued a $20.00 target price on shares of Greenhill & Co., Inc. in a report on Thursday, April 12th. Finally, Keefe, Bruyette & Woods cut shares of Greenhill & Co., Inc. from a “market perform” rating to an “underperform” rating and raised their target price for the stock from $22.00 to $25.00 in a report on Wednesday, June 6th. Four equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $18.43.

Shares of Greenhill & Co., Inc. opened at $29.80 on Thursday, according to Marketbeat.com. Greenhill & Co., Inc. has a one year low of $13.80 and a one year high of $29.85. The stock has a market capitalization of $674.76 million, a price-to-earnings ratio of -102.50 and a beta of 1.12. The company has a quick ratio of 4.71, a current ratio of 4.71 and a debt-to-equity ratio of 1.97.

Greenhill & Co., Inc. (NYSE:GHL) last announced its earnings results on Thursday, May 3rd. The financial services provider reported $0.21 EPS for the quarter, topping the consensus estimate of ($0.04) by $0.25. Greenhill & Co., Inc. had a negative net margin of 7.24% and a negative return on equity of 0.10%. The company had revenue of $87.50 million during the quarter, compared to analysts’ expectations of $63.61 million. During the same period last year, the company posted ($0.02) earnings per share. The business’s revenue for the quarter was up 53.8% on a year-over-year basis. analysts anticipate that Greenhill & Co., Inc. will post 1.1 earnings per share for the current fiscal year.

In other news, President David Wyles sold 29,242 shares of the stock in a transaction that occurred on Friday, May 11th. The shares were sold at an average price of $25.62, for a total value of $749,180.04. Following the completion of the sale, the president now directly owns 24,388 shares of the company’s stock, valued at $624,820.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 15.60% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. First Mercantile Trust Co. raised its position in Greenhill & Co., Inc. by 94.6% during the first quarter. First Mercantile Trust Co. now owns 10,573 shares of the financial services provider’s stock valued at $196,000 after acquiring an additional 5,139 shares in the last quarter. Quantitative Systematic Strategies LLC bought a new position in Greenhill & Co., Inc. during the first quarter valued at approximately $216,000. Paloma Partners Management Co bought a new position in Greenhill & Co., Inc. during the fourth quarter valued at approximately $251,000. MetLife Investment Advisors LLC bought a new position in Greenhill & Co., Inc. during the fourth quarter valued at approximately $269,000. Finally, Virtu Financial LLC bought a new position in Greenhill & Co., Inc. during the fourth quarter valued at approximately $384,000. 96.88% of the stock is owned by institutional investors and hedge funds.

About Greenhill & Co., Inc.

Greenhill & Co, Inc, together with its subsidiaries, operates as an independent investment bank for corporations, partnerships, institutions, and governments worldwide. The company provides financial advisory services primarily related to mergers and acquisitions, restructurings, financings, and capital raisings.

Get a free copy of the Zacks research report on Greenhill & Co., Inc. (GHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Financial Survey: Switch (SWCH) versus Sabre (SABR)

Switch (NYSE: SWCH) and Sabre (NASDAQ:SABR) are both mid-cap business services companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, earnings and profitability.

Profitability

Get Switch alerts:

This table compares Switch and Sabre’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Switch	N/A	N/A	N/A
Sabre	6.93%	49.84%	6.21%

Analyst Ratings

This is a breakdown of recent ratings for Switch and Sabre, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Switch	0	5	7	0	2.58
Sabre	1	2	7	0	2.60

Switch currently has a consensus price target of $20.00, suggesting a potential upside of 61.16%. Sabre has a consensus price target of $25.00, suggesting a potential downside of 3.66%. Given Switch’s higher possible upside, analysts clearly believe Switch is more favorable than Sabre.

Institutional & Insider Ownership

14.1% of Switch shares are owned by institutional investors. 12.6% of Switch shares are owned by company insiders. Comparatively, 0.7% of Sabre shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Dividends

Switch pays an annual dividend of $0.06 per share and has a dividend yield of 0.5%. Sabre pays an annual dividend of $0.56 per share and has a dividend yield of 2.2%. Sabre pays out 43.1% of its earnings in the form of a dividend.

Valuation & Earnings

This table compares Switch and Sabre’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Switch	$378.27 million	8.29	-$15.20 million	N/A	N/A
Sabre	$3.60 billion	1.98	$242.53 million	$1.30	19.96

Sabre has higher revenue and earnings than Switch.

Summary

Sabre beats Switch on 7 of the 12 factors compared between the two stocks.

Switch Company Profile

Switch, Inc., through its subsidiary, Switch, Ltd., provides colocation space and related services to technology and digital media companies, cloud and managed service providers, financial institutions, and telecommunications providers that conduct critical business on the Internet. The company develops and operates data centers in Nevada, Michigan, and Georgia. Switch, Inc. was founded in 2000 and is headquartered in Las Vegas, Nevada.

Sabre Company Profile

Sabre Corporation, through its subsidiary, Sabre Holdings Corporation, provides technology solutions to the travel and tourism industry worldwide. It operates through two segments, Travel Network, and Airline and Hospitality Solutions. The Travel Network segment operates as a business-to-business travel marketplace that offers travel content, such as inventory, prices, and availability from a range of travel suppliers, including airlines, hotels, car rental brands, rail carriers, cruise lines, and tour operators with a network of travel buyers comprising online and offline travel agencies, travel management companies, and corporate travel departments. The Airline and Hospitality Solutions segment provides a portfolio of software technology products and solutions through software-as-a-service and hosted delivery models to airlines, hoteliers, and other travel suppliers. Its products include SabreSonic Customer Sales & Service, a reservation system that provides capabilities around managing sales and customer service across an airline's diverse touch points; Sabre AirVision Marketing & Planning, a set of airline commercial planning solutions; and Sabre AirCentre Enterprise Operations, a set of solutions for planning and management of airline, airport, and customer operations. This segment also provides software and solutions to hoteliers through SynXis, a central reservation system; SynXis Property Manager Solution for property management; and marketing, professional, and revenue management services. Sabre Corporation was founded in 2006 and is headquartered in Southlake, Texas.

Hot Biotech Stocks To Buy For 2019

tags:BIIB,ALNY,ARQL,AMGN,

Clinical-stage biotechs can be veritable goldmines for patient investors. The caveat, however, is that it can immensely difficult to predict which companies are actually worth the wait.

For instance, the developmental biotech Cara Therapeutics (NASDAQ:CARA) has been making steady progress in the clinic with its novel kappa receptor agonist, Korsuva (CR845), over the past few years. If approved, this drug should generate tremendous upside for investors, but there's also substantial risks involved for early shareholders at this stage of the game.

Image source: Getty Images.

As such, I think it's definitely worth contemplating where this promising clinical-stage biotech might be in five years from now -- that is, prior to buying shares. Let's dig in to find out.��

Cara's present

Korsuva is in early- to late-stage trials for various pruritus (itching) indications, as well as acute postoperative pain.�The big draw here for investors is that this experimental drug is designed to be far less addictive than traditional opioids, potentially making it a powerful new tool in the battle against the raging opioid epidemic.

Hot Biotech Stocks To Buy For 2019: Biogen Idec Inc(BIIB)

Advisors' Opinion:

• [By Keith Speights]

  Shares of Biogen Inc. (NASDAQ:BIIB) were up 15.2% as of 11:35 a.m. EDT on Friday after the biotech, along with partner Eisai, reported encouraging results from a phase 2 clinical study of BAN2401 in treating Alzheimer's disease. Patients taking BAN2401 achieved statistically significant�improvement compared to patients on placebo after 18 months in�slowing progression of Alzheimer's disease and in the reduction�of�amyloid�accumulations in�the brain.

• [By Chris Lange]

  The S&P 500 stock posting the largest daily percentage loss ahead of the close Wednesday was Biogen Inc. (NASDAQ: BIIB) which traded down about 6% at 297.99. The stock��s 52-week range is $244.28 to $370.67. Volume was about 5 million compared to the daily average volume of roughly 1 million.

• [By Chris Lange]

  Short interest in Biogen Inc. (NASDAQ: BIIB) increased to 3.50 million shares from the previous 3.16 million. The stock recently traded at $262.15, within a 52-week range of $244.28 to $370.57.

Hot Biotech Stocks To Buy For 2019: Alnylam Pharmaceuticals Inc.(ALNY)

Advisors' Opinion:

• [By Keith Speights]

  I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick -- but with a couple of qualifications. First, I didn't think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.

• [By Logan Wallace]

  Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company.  However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”

• [By Shane Hupp]

  Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

  For more information about research offerings from Zacks Investment Research, visit Zacks.com

• [By Brian Orelli]

  The delay in an FDA decision for Tegsedi puts it behind competitor Alnylam Pharmaceuticals (NASDAQ:ALNY), which expects to hear from the FDA by Aug. 11 for its hATTR drug patisiran. But Sarah Boyce, the president at Akcea Therapeutics, doesn't think a few months will really matter: "We don't really feel that's going to have any impact and the drugs will be close enough together from a launch perspective. So not really [going] to make any adjustments, and we're very well prepared to be ready to launch following approval."

• [By Joseph Griffin]

  BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.

• [By Sean Williams, Chuck Saletta, and Brian Feroldi]

  So, which biotech stocks should you consider buying in June? That's a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).

Hot Biotech Stocks To Buy For 2019: ArQule Inc.(ARQL)

Advisors' Opinion:

• [By Lisa Levin] Gainers Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares surged 20.6 percent to $6.39. WBB Securities upgraded Melinta Therapeutics from Hold to Speculative Buy. Shoe Carnival, Inc. (NASDAQ: SCVL) shares climbed 17.2 percent to $30.87 after the company reported upbeat quarterly earnings. Acorn International, Inc. (NYSE: ATV) shares rose 15.2 percent to $28.804 after the company declared a special one-time cash dividend of $14.97 per ADS. Foot Locker, Inc. (NYSE: FL) gained 15 percent to $53.35 after the company reported better-than-expected results for its first quarter. Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) surged 14.2 percent to $2.625. ArQule, Inc. (NASDAQ: ARQL) rose 13 percent to $5.12 after gaining 4.86 percent on Thursday. Quality Systems, Inc. (NASDAQ: QSII) gained 12.8 percent to $16.97 after the company posted better-than-expected FQ4 results. Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE: LOMA) shares rose 12 percent to $12.94. ArQule, Inc. (NASDAQ: ARQL) shares rose 12 percent to $5.07. Mirati Therapeutics, Inc. (NASDAQ: MRTX) climbed 11.4 percent to $43.50. Zai Lab Limited (NASDAQ: ZLAB) gained 11.3 percent to $24.7000. Zymeworks Inc. (NASDAQ: ZYME) rose 9.7 percent to $19.64. Park City Group, Inc. (NASDAQ: PCYG) climbed 9 percent to $7.90. Roku, Inc. (NASDAQ: ROKU) gained 7.9 percent to $38.82 after Citron reversed previously bearish position on the stock. Sears Holdings Corporation (NASDAQ: SHLD) shares jumped 7.3 percent to $3.55. Deckers Outdoor Corp (NYSE: DECK) rose 3.5 percent to $107.27 after reporting better-than-expected results for its fiscal fourth quarter.

  Check out these big penny stock gainers and losers

• [By Lisa Levin] Gainers Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter. Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants. Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday. SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday. Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results. Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter. Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday. Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday. ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday. Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday. Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.

  Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.

• [By Joseph Griffin]

  ValuEngine upgraded shares of ArQule (NASDAQ:ARQL) from a buy rating to a strong-buy rating in a research report released on Tuesday.

  Several other equities analysts have also issued reports on ARQL. Zacks Investment Research upgraded ArQule from a hold rating to a buy rating and set a $2.50 price objective for the company in a research report on Tuesday, March 20th. BidaskClub upgraded ArQule from a buy rating to a strong-buy rating in a research report on Saturday, March 24th. B. Riley set a $4.00 price objective on ArQule and gave the company a buy rating in a research report on Monday, March 26th. Leerink Swann upgraded ArQule from a market perform rating to an outperform rating in a research report on Thursday, April 5th. Finally, Roth Capital boosted their price objective on ArQule from $5.00 to $6.00 and gave the company a buy rating in a research report on Tuesday, April 17th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. The company has a consensus rating of Buy and a consensus target price of $5.35.

Hot Biotech Stocks To Buy For 2019: Amgen Inc.(AMGN)

Advisors' Opinion:

• [By Keith Speights]

  Amgen (NASDAQ:AMGN) has been the hands-down winner over Celgene (NASDAQ:CELG) in terms of stock performance over the last year. It's the same story for revenue generated. Celgene beat Amgen in earnings, but only because of a technicality: Amgen incurred a big one-time tax hit in 2017.

• [By Max Byerly]

  Amgen (NASDAQ: AMGN) and aTyr Pharma (NASDAQ:LIFE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

• [By Chris Lange]

  Amgen Inc. (NASDAQ: AMGN) saw its short interest fall slightly to 10.61 million shares from the previous level of 10.72 million. Shares were last seen at $184.59, in a 52-week trading range of $163.31 to $201.23.

Envion 1-Day Trading Volume Tops $24,196.00 (EVN)

Envion (CURRENCY:EVN) traded 1.2% higher against the dollar during the 24 hour period ending at 12:00 PM Eastern on July 5th. Envion has a total market capitalization of $15.36 million and approximately $24,196.00 worth of Envion was traded on exchanges in the last day. One Envion token can now be bought for $0.14 or 0.00002085 BTC on major exchanges including Token Store, YoBit, HitBTC and IDEX. Over the last seven days, Envion has traded 1.8% higher against the dollar.

Here’s how related cryptocurrencies have performed over the last day:

Get Envion alerts: XRP (XRP) traded down 1.8% against the dollar and now trades at $0.49 or 0.00007339 BTC. Stellar (XLM) traded down 2.7% against the dollar and now trades at $0.21 or 0.00003134 BTC. IOTA (MIOTA) traded 3.8% lower against the dollar and now trades at $1.18 or 0.00017757 BTC. NEO (NEO) traded 8.6% higher against the dollar and now trades at $42.07 or 0.00635734 BTC. Tether (USDT) traded up 0.7% against the dollar and now trades at $1.01 or 0.00015224 BTC. TRON (TRX) traded down 2.6% against the dollar and now trades at $0.0386 or 0.00000583 BTC. Binance Coin (BNB) traded down 1.3% against the dollar and now trades at $13.92 or 0.00210269 BTC. VeChain (VET) traded down 4.1% against the dollar and now trades at $2.63 or 0.00039772 BTC. Ontology (ONT) traded 2.6% lower against the dollar and now trades at $5.05 or 0.00076245 BTC. Zilliqa (ZIL) traded 0.4% higher against the dollar and now trades at $0.0866 or 0.00001308 BTC.

Envion Profile

Envion’s launch date was January 31st, 2018. Envion’s total supply is 127,425,494 tokens and its circulating supply is 111,298,337 tokens. Envion’s official Twitter account is @envion_org and its Facebook page is accessible here. The official website for Envion is www.envion.org.

Envion Token Trading

Envion can be purchased on the following cryptocurrency exchanges: IDEX, YoBit, Token Store and HitBTC. It is usually not possible to buy alternative cryptocurrencies such as Envion directly using U.S. dollars. Investors seeking to acquire Envion should first buy Ethereum or Bitcoin using an exchange that deals in U.S. dollars such as GDAX, Gemini or Coinbase. Investors can then use their newly-acquired Ethereum or Bitcoin to buy Envion using one of the aforementioned exchanges.

new TradingView.widget({ “height”: 400, “width”: 650, “symbol”: “EVNUSD”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Brokerages Anticipate Bemis Company, Inc. (BMS) Will Post Earnings of $0.63 Per Share

Equities research analysts forecast that Bemis Company, Inc. (NYSE:BMS) will post earnings of $0.63 per share for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Bemis’ earnings, with the highest EPS estimate coming in at $0.70 and the lowest estimate coming in at $0.57. Bemis posted earnings per share of $0.48 in the same quarter last year, which would suggest a positive year over year growth rate of 31.3%. The company is scheduled to report its next quarterly earnings results before the market opens on Thursday, July 26th.

According to Zacks, analysts expect that Bemis will report full-year earnings of $2.79 per share for the current financial year, with EPS estimates ranging from $2.70 to $2.85. For the next financial year, analysts forecast that the company will post earnings of $3.06 per share, with EPS estimates ranging from $2.81 to $3.15. Zacks’ EPS averages are an average based on a survey of research analysts that that provide coverage for Bemis.

Get Bemis alerts:

Bemis (NYSE:BMS) last released its earnings results on Thursday, April 26th. The industrial products company reported $0.63 EPS for the quarter, beating the Zacks’ consensus estimate of $0.60 by $0.03. The company had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1 billion. Bemis had a return on equity of 17.91% and a net margin of 2.22%. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.58 EPS.

A number of research analysts have recently commented on the company. Zacks Investment Research upgraded Bemis from a “hold” rating to a “buy” rating and set a $50.00 target price for the company in a research note on Thursday, April 5th. Citigroup lowered their target price on Bemis from $49.00 to $46.00 and set a “neutral” rating for the company in a research note on Thursday, April 5th. KeyCorp restated a “hold” rating on shares of Bemis in a research note on Thursday, April 26th. TheStreet upgraded Bemis from a “c” rating to a “b-” rating in a research note on Thursday, April 26th. Finally, Bank of America upgraded Bemis from an “underperform” rating to a “buy” rating and set a $50.00 target price for the company in a research note on Monday, April 2nd. Four research analysts have rated the stock with a sell rating, six have assigned a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $48.67.

Shares of Bemis traded down $0.11, reaching $42.25, on Tuesday, according to Marketbeat Ratings. The stock had a trading volume of 431,100 shares, compared to its average volume of 602,709. The stock has a market cap of $3.84 billion, a PE ratio of 17.68, a PEG ratio of 2.16 and a beta of 0.85. The company has a quick ratio of 0.96, a current ratio of 1.88 and a debt-to-equity ratio of 1.25. Bemis has a 12-month low of $40.60 and a 12-month high of $49.84.

A number of large investors have recently made changes to their positions in BMS. Hsbc Holdings PLC increased its holdings in shares of Bemis by 1.4% in the 1st quarter. Hsbc Holdings PLC now owns 89,950 shares of the industrial products company’s stock worth $3,914,000 after purchasing an additional 1,268 shares in the last quarter. Whittier Trust Co. increased its holdings in shares of Bemis by 2.0% in the 1st quarter. Whittier Trust Co. now owns 65,696 shares of the industrial products company’s stock worth $2,859,000 after purchasing an additional 1,316 shares in the last quarter. Flinton Capital Management LLC increased its holdings in shares of Bemis by 1.0% in the 4th quarter. Flinton Capital Management LLC now owns 139,162 shares of the industrial products company’s stock worth $6,651,000 after purchasing an additional 1,326 shares in the last quarter. LPL Financial LLC increased its holdings in shares of Bemis by 9.1% in the 1st quarter. LPL Financial LLC now owns 21,371 shares of the industrial products company’s stock worth $930,000 after purchasing an additional 1,786 shares in the last quarter. Finally, American International Group Inc. increased its holdings in shares of Bemis by 1.1% in the 4th quarter. American International Group Inc. now owns 187,895 shares of the industrial products company’s stock worth $8,980,000 after purchasing an additional 2,127 shares in the last quarter. Institutional investors and hedge funds own 75.06% of the company’s stock.

Bemis Company Profile

Bemis Company, Inc manufactures and sells packaging products in the United States, Brazil, other Americas, Europe, and the Asia-Pacific. It operates through three segments: U.S. Packaging, Latin America Packaging, and Rest of World Packaging. The company offers multilayer polymer, blown, and cast film structures; and injection molded plastic, thermoformed plastic, and folding carton packaging products.

Get a free copy of the Zacks research report on Bemis (BMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com